Gilead Sciences (NASDAQ:GILD) Now Covered by Analysts at Wolfe Research

Wolfe Research assumed coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research note released on Friday, Marketbeat reports. The firm issued an outperform rating and a $110.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on GILD. Robert W. Baird raised their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Truist Financial lifted their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a report on Friday, November 8th. Finally, Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Eleven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $94.00.

Gilead Sciences Stock Up 0.1 %

NASDAQ GILD opened at $88.46 on Friday. Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $98.90. The firm has a market capitalization of $110.24 billion, a price-to-earnings ratio of 982.89, a PEG ratio of 2.72 and a beta of 0.17. The company has a quick ratio of 0.82, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a fifty day moving average of $86.87 and a two-hundred day moving average of $76.27.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the firm posted $2.29 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year. On average, analysts predict that Gilead Sciences will post 4.38 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.48%. Gilead Sciences’s payout ratio is 3,422.22%.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,947 shares of company stock worth $4,968,674 in the last ninety days. 0.16% of the stock is owned by insiders.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds have recently made changes to their positions in GILD. CarsonAllaria Wealth Management Ltd. grew its stake in Gilead Sciences by 198.3% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 238 shares during the last quarter. nVerses Capital LLC purchased a new stake in Gilead Sciences in the third quarter valued at approximately $25,000. Valued Wealth Advisors LLC increased its holdings in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the period. Cedar Wealth Management LLC raised its position in Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 160 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the 2nd quarter valued at approximately $33,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.